<SEC-DOCUMENT>0001104659-24-052455.txt : 20240426
<SEC-HEADER>0001104659-24-052455.hdr.sgml : 20240426
<ACCEPTANCE-DATETIME>20240426080033
ACCESSION NUMBER:		0001104659-24-052455
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240426
DATE AS OF CHANGE:		20240426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		24878862

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>tm2412633d1_10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:EYEN="http://eyenoviabio.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_EYEN_eyenoviabio.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001682639 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001682639</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="eyen-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20230101__20231231_zmwFhgVC21ab"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000013" name="dei:DocumentType">10-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amendment No. 1</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--DocumentAnnualReport_c20230101__20231231_zZyK5accPJhe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">x</ix:nonNumeric></span></span></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 96%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal&#160;year ended: <span id="xdx_903_edei--DocumentPeriodEndDate_c20230101__20231231_z6xIUNWUJ3nd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">December 31,
2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt"><b><span style="font-family: Wingdings"><span id="xdx_901_edei--DocumentTransitionReport_c20230101__20231231_z4UPGYZ8piS6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#168;</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from _________________
to ______________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>COMMISSION FILE NUMBER: <span id="xdx_902_edei--EntityFileNumber_c20230101__20231231_zEb4gu1TCgfd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000017" name="dei:EntityFileNumber">001-38365</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20230101__20231231_zX9NIqtZ8Kha"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityRegistrantName">EYENOVIA, INC.</ix:nonNumeric></span></b></p>

<p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name
of Registrant as Specified in Its Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zXxn6HdNMrb6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">delaware</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230101__20231231_zSh6nL7DD2qg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">47-1178401</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in; text-align: center; text-indent: -0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in; text-align: center; text-indent: -0.1in">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; padding-left: 0.1in; text-align: center; text-indent: -0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230101__20231231_zWFnTj7vJCHe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:EntityAddressAddressLine1">295 Madison Avenue</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20230101__20231231_zhEXab9Vs6Ng"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityAddressAddressLine2">Suite&#160;2400</ix:nonNumeric></span><br/>
<span id="xdx_901_edei--EntityAddressCityOrTown_c20230101__20231231_zwOxfCfN0QG2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressCityOrTown">NEW YORK</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20230101__20231231_zCrZAVHnRXU"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20230101__20231231_zHC6r4vgerSc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">10017&#160;</ix:nonNumeric></span></b></p></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in; text-align: center; text-indent: -0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: <span id="xdx_909_edei--CityAreaCode_c20230101__20231231_zbGO9AFbreAi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000026" name="dei:CityAreaCode">(833)</ix:nonNumeric></span> <span id="xdx_90C_edei--LocalPhoneNumber_c20230101__20231231_zpSlrZZ9IX2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:LocalPhoneNumber">393-6684</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which<br/>
registered</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--Security12bTitle_c20230101__20231231_zwTofdKtn3gk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:Security12bTitle">Common Stock, $0.0001 Par Value</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--TradingSymbol_c20230101__20231231_zKGn8f1GFHQ2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:TradingSymbol">EYEN</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--SecurityExchangeName_c20230101__20231231_zkdzaMrwcP93"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section&#160;12(g)&#160;of
the Act: none</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family: Wingdings">&#168;</span>
<span id="xdx_90C_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zY30WIxZsElb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000031" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Wingdings"><span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes
</span><span style="font-family: Wingdings">&#168;</span> <span id="xdx_90F_edei--EntityVoluntaryFilers_c20230101__20231231_zwjTUEyGY1T6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000032" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Wingdings"><span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate by
check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities
Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports),
and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <span id="xdx_903_edei--EntityCurrentReportingStatus_c20230101__20231231_zJJF5KQAMAQ2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> </span><span style="font-family: Wingdings">x</span>
No <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate by
check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405
of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_909_edei--EntityInteractiveDataCurrent_c20230101__20231231_zatWa1gqxAC2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> </span><span style="font-family: Wingdings">x</span> No <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span><span style="font-family: Wingdings; font-size: 10pt">&#168;</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span><span style="font-family: Wingdings; font-size: 10pt">&#168;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20230101__20231231_z1plNHZNyEBj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span><span style="font-family: Wingdings">x</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span><span style="font-family: Wingdings"><span id="xdx_90C_edei--EntitySmallBusiness_c20230101__20231231_zS2S1gDBn1w5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">x</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span><span style="font-family: Wingdings; font-size: 10pt"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20230101__20231231_ztDuK0J0oIJ2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
news or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate by
check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If securities
are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included
in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate by
check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received
by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes </span><span style="font-family: Wingdings">&#168;</span>
<span id="xdx_90A_edei--EntityShellCompany_c20230101__20231231_zHYkDwsSQEck"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Wingdings">x</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%; padding-right: 5.4pt; padding-bottom: 2pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor PCAOB ID Number: <span id="xdx_900_edei--AuditorFirmId_c20230101__20231231_zNyC9fjHMgRc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000039" name="dei:AuditorFirmId">688</ix:nonNumeric></span></span></td>
    <td style="width: 34%; padding-right: 5.4pt; padding-bottom: 2pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor Name: <span id="xdx_90F_edei--AuditorName_c20230101__20231231_zHJE1IAA0RZa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000040" name="dei:AuditorName">Marcum LLP</ix:nonNumeric></span></span></td>
    <td style="width: 33%; padding-right: 5.4pt; padding-bottom: 2pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor Location: <span id="xdx_908_edei--AuditorLocation_c20230101__20231231_z4Cfsc4DlmHe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000041" name="dei:AuditorLocation">New York, NY</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the price at which the common equity was last sold as of June&#160;30, 2023 (based on
the closing price of $2.37 on June 30, 2023, the last trading day of the registrant&#8217;s most recently completed second fiscal quarter),
was approximately $<span id="xdx_90E_edei--EntityPublicFloat_iI_pn5n6_c20230630_z2ifOL7bGV3j"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">88.0</ix:nonFraction></span> million. Common stock held by each officer and director and by each person known to the registrant who owned 10%
or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of
affiliate status is not necessarily a conclusive determination for other purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of outstanding shares of the registrant&#8217;s
common stock was <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20240416_zNzdUpEsKrj6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-04-16" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,957,869</ix:nonFraction></span> as of April 16, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Explanatory Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eyenovia, Inc. (the &#8220;Company,&#8221; &#8220;Eyenovia,&#8221;
 &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is filing this Amendment No. 1 on Form 10-K/A (this &#8220;Form 10-K/A&#8221;)
to amend the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the &#8220;2023 10-K&#8221;), which
was originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 18, 2024, to include the information
required by Items 10 through 14 of Part III of the 2023 10-K. This information was previously omitted from the 2023 10-K in reliance on
General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K
by reference from the Company&#8217;s definitive proxy statement if such statement is filed no later than 120 days after the Company&#8217;s
fiscal year-end. This Form 10-K/A amends and restates in its entirety Items 10, 11, 12, 13 and 14 of Part III of the 2023 10-K. The cover
page of the 2023 10-K is also amended to (i) update the number of outstanding shares of common stock as of April 16, 2024, and (ii) delete
the reference to the incorporation by reference of the Company&#8217;s definitive proxy statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;), this Form 10-K/A amends Item 15 of Part&#160;&#160;IV of the 2023 10-K solely to update the
exhibit list to include new certifications by our principal executive officer and principal financial officer under Section 302 of the
Sarbanes-Oxley Act of 2002. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain
or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of these certifications have been omitted.
Similarly, because no financial statements have been included in this Form 10-K/A, certifications pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 have been omitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as described above, no other changes have been made to the 2023
10-K, and this Form 10-K/A does not modify, amend or update in any way any of the financial or other information contained in the 2023
10-K. This Form 10-K/A does not reflect events occurring after the date of the filing of the 2023 10-K, nor does it amend, modify or otherwise
update any other information in the 2023 10-K. Accordingly, this Form 10-K/A should be read in conjunction with the 2023 10-K and with
the Company&#8217;s filings with the SEC subsequent to the filing of the 2023 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 95%"><a href="#toc_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part III</span></a></td>
    <td style="width: 5%; text-align: right"><a href="#toc_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.&#160;&#160;Directors,&#160;Executive Officers and Corporate Governance.</span></a></td>
    <td style="text-align: right"><a href="#toc_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11. Executive Compensation.</span></a></td>
    <td style="text-align: right"><a href="#toc_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></td>
    <td style="text-align: right"><a href="#toc_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></a></td>
    <td style="text-align: right"><a href="#toc_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14. Principal Accountant Fees and Services.</span></a></td>
    <td style="text-align: right"><a href="#toc_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part IV</span></a></td>
    <td style="text-align: right"><a href="#toc_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&#160;</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#toc_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15. Exhibits.</span></a></td>
    <td style="text-align: right"><a href="#toc_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&#160;</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="toc_001"></span>Part III</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_002"></span>Item 10.&#160;&#160;Directors,&#160;Executive Officers and Corporate
Governance.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board of Directors currently consists of seven
members, each of whom serve for a one-year term or until a successor has been elected and qualified: Tsontcho Ianchulev, M.D., M.P.H.,
Michael Geltzeiler, Rachel Jacobson, Charles E. Mather IV, Ram Palanki, Pharm.D., Michael Rowe and Ellen Strahlman, M.D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The name of and certain information regarding
each director as of April 16, 2024 is set forth below. This information is based on data furnished to us by the directors. There is no
family relationship between any director, executive officer, or person nominated to become a director or executive officer. The business
address for each director for matters regarding the Company is 295 Madison Avenue, Suite 2400, New York, NY 10017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; float: right; width: 97%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 36%; padding-right: 5.4pt">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Name of Director </b></p></td>
    <td style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Age</b></p></td>
    <td style="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Positions
    with Eyenovia</b></p></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Director Since</b></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev, M.D., M.P.H. </span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2014 </span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Geltzeiler</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2023</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rachel Jacobson </span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2022</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles E. Mather IV </span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2018 </span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Palanki, Pharm.D.&#160;&#160;</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2022</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Rowe </span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022 </span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen Strahlman, M.D.</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2022 </span></td></tr>
  </table><div style="clear: both"></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Tsontcho Ianchulev&#8201;-&#8201; Executive Chairman</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Ianchulev has been serving as a member of
our Board of Directors since March 2014. Dr. Ianchulev was the Chief Executive Officer of our Company from 2017 to 2022, and became the
Executive Chairman of our Board in August 2022. Dr. Ianchulev is a Harvard-trained physician-executive, ophthalmic surgeon, inventor and
serial entrepreneur, who has been at the forefront of medical innovation and products that have transformed the ophthalmic field. Currently,
Dr. Ianchulev is a Professor of Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai in New York City. Previously, while at
Genentech, Inc., Dr. Ianchulev headed the ophthalmology clinical research group and directed the development and the FDA approval of Lucentis&#174;,
one of the most successful biotech innovations in the field of ophthalmology. As an inventor and developer, Dr. Ianchulev has participated
in the development of many breakthrough technologies and venture-funded acquisitions &#8212; from the first ophthalmic intraoperative
biometry device (Alcon, Inc.), the only FDA-approved suprachoroidal MIGS micro-stent (Alcon, Inc.), the first biologic stent technology
in ophthalmology (Iantrek, Inc.), the original micro- interventional cataract fragmentation system (miLOOP, Zeiss Meditec) as well as
the first microdose smart delivery system for topical therapeutics (Eyenovia, Inc.). Dr. Ianchulev&#8217;s robotics team at New York Eye
and Ear Infirmary and his pioneering work with Preceyes, Inc. led to the introduction of micro- interventional robotics in ophthalmic
surgery (Zeiss Meditec). Dr. Ianchulev received his B.S. from the University of Rochester, received both his medical degree (MD) and a
Master of Public Health (MPH) degree from Harvard University and completed his specialty training at the Doheny Eye Institute. Dr. Ianchulev
is a holder of many issued and pending patents. He has also participated in multiple publications in the field, which have been cited
by more than 3,000 peer-reviewed publications. He also sits on several corporate and scientific advisory Boards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that Dr. Ianchulev&#8217;s experience
in drug discovery and development of pharmaceutical products and in the operation of biopharmaceutical businesses is valuable to the Company
and qualifies him to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Michael Geltzeiler &#8212; Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Geltzeiler has been a member of the Board
of Directors since November 2023. Mr. Geltzeiler brings to the Board significant expertise as a chief financial officer of public companies.
Mr. Geltzeiler served as chief financial officer at ADT Corporation from November 2013 &#8211; June 2016. Prior to that, Mr. Geltzeiler
served as chief financial officer of NYSE Euronext from June 2008 &#8211; November 2013. Mr. Geltzeiler served as a director of Cypress
Creek Renewables, a private company, from October 2018 to December 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Mr. Geltzeiler&#8217;s significant
experience as a Chief Financial Officer of companies including ADT Corporation, Euronext and Readers Digest, and his extensive finance
background, is valuable to the Company and qualifies him to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Rachel Jacobson&#8201;-&#8201;Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ms. Jacobson has been a member of the Board of
Directors since February 2022. Ms. Jacobson brings to the Board significant expertise in business development and marketing, having served
in leadership positions at major global sports organizations including the Drone Racing League (&#8220;DRL&#8221;) and the National Basketball
Association (&#8220;NBA&#8221;). Currently, Ms. Jacobson serves as the President of DRL, the world&#8217;s premier, professional drone
racing property, where she spearheads global partnerships and media rights deals, and leads the marketing and business development teams.
Bringing to DRL her legacy of creating transformative partnerships with leading sports and technology brands, Rachel has forged groundbreaking
partnerships with organizations including Algorand, Google, T-Mobile, New Balance, the U.S. Air Force, PointsKash, and Draganfly. Laser
focused on making a global, philanthropic impact, she also expanded the league&#8217;s DRL Academy STEM program with Steve Wozniak&#8217;s
Woz Ed to create a new, interactive drone racing curriculum for students around the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to DRL, she served as the Chief Business
Development Officer at Landit, Inc., the market leader in personalized career pathing technology to increase the success and engagement
of women and diverse groups in the workplace. Before that, she spent 21 years at the NBA, where she oversaw business development, licensing,
marketing, account management, event planning, and held several other roles during her tenure. As their SVP of Global Partnerships, she
closed partnership sales and secured global partnerships with some of the world&#8217;s most prominent companies including PepsiCo, Inc.,
ExxonMobil Corporation, Under Armour, Inc., Marriott International Inc., Harman International Industries, Kaiser Permanente and other
Fortune 500 companies. Ms. Jacobson has received numerous industry accolades, including being named a Fortune&#8217;s Most Powerful Women
member, Cynopsis Top Women in Media&#8217;s &#8220;Innovator &amp; Disruptor,&#8221; TechStars Sports Accelerator Mentor and a recipient
of Sports Business Journal&#8217;s 40 Under 40 Award. She is a charter member of the W.O.M.E.N. Mentoring Program, where she helps other
professional women advance their careers through leadership training. Ms. Jacobson is a graduate of the Cornell University School of Hotel
 &amp; Business Management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Ms. Jacobson&#8217;s significant experience
in business development and marketing is valuable to the Company and qualifies her to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Charles E. Mather IV&#8201;-&#8201;Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Mather has been a member of our Board of Directors
since March 2018. He currently serves as Senior Managing Director at Brookline Capital Markets. From October 2019 until January 2023,
Mr. Mather was Managing Director, Head of Life Sciences and Medical Technology Capital Markets at Truist Securities, Inc. (f/k/a Suntrust
Robinson Humphrey, Inc.) Prior to that, from March 2015 to September 2019, Mr. Mather was Managing Director, Co-Head of Equity Capital
Markets at BTIG, LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From December 2009 to February 2015, he was the
Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott LLC. Prior to that, Mr. Mather
held various senior investment banking positions at Jefferies Group, Inc. and Cowen and Company, LLC. Mr. Mather serves on the board of
Wentz Holdings, Inc. Mr. Mather also served on the board of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) until February 2019 and
the Finance Company of Pennsylvania until June 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance
from The Wharton School at the University of Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Mr. Mather&#8217;s extensive experience
advising life science companies as an investment banker and prior board experience is valuable to the Company and qualifies him to serve
as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ram Palanki, Pharm.D. &#8211; Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Ram Palanki has been a member of the Board
of Directors since July 2022. He currently serves as Executive Vice President of Commercial Strategy &amp; Operations at REGENXBIO, Inc.
(Nasdaq: RGNX), a leader in AAV gene therapy, and is responsible for the planning, execution, and commercialization of their pipeline
across the ophthalmology, central nervous system, and neuromuscular disease franchises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Palanki has nearly 20 years of experience
in the development and commercialization of biopharmaceuticals and medical devices. Before joining REGENXBIO, Inc., Dr. Palanki was Senior
Vice President of Commercial for the Americas at Santen Inc. Previously, he served as the executive team member leading the strategy and
operations for pre-launch and global commercialization of a first-in-class biologic at ThromboGenics NV (now known as Oxurion, Euronext
Brussels: OXUR). Over the span of his career, Dr. Palanki has held roles of increasing responsibility at several small, mid-sized and
large companies, including the launch of LUCENTIS&#174; at Genentech, Inc. He is an active board member and strategic advisor to multiple
biotech companies, technology start-ups and global non-profits, including AAVantgarde Bio and Orbis International.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Palanki holds a Pharm.D. from Albany College
of Pharmacy, Union University and his post doctorate from Rutgers University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Dr. Palanki&#8217;s extensive experience
as a leader in the life sciences industry is valuable to the Company and qualifies him to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Michael Rowe &#8211; Chief Executive Officer and Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Michael Rowe has been the Chief Executive Officer
and a member of the Board of Directors since August 2022. Prior to these roles, he served as the Company&#8217;s Corporate Vice President
from 2018 to 2021 and the Chief Operating Officer from 2021 until being named Chief Executive Officer. Previously, Mr. Rowe was the Executive
Director of Marketing for Aerie Pharmaceuticals Inc., where he was pivotal in the commercialization of their glaucoma franchise. Before
that, Mr. Rowe spent 12 years at Allergan plc, where he found the health economics department, led strategic planning and new pharmaceutical
and device product commercialization for the global glaucoma franchise and found the competitive intelligence function across the company.
During this time, Mr. Rowe also served as the Company&#8217;s liaison with Senju Pharmaceuticals (&#8220;Senju&#8221;) (a current stockholder
and licensee of Eyenovia) and was instrumental in the successful launch of multiple glaucoma products in the Japanese market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Rowe received his B.A. in Psychology from
the State University of New York, Stony Brook and his Masters of Science in Experimental Psychology and Ergonomics from Rensselaer Polytechnic
Institute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Mr. Rowe's experience as an executive
of the Company and as our Chief Executive Officer is valuable to the Company and qualifies him to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ellen Strahlman, M.D., MHSc &#8211; Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Strahlman has been a member of the Board of
Directors since July 2022. She currently serves as Partner at Reillen Group LLC. She previously served as Executive Vice President, Research
 &amp; Development and Chief Medical Officer of Becton, Dickinson and Company (&#8220;BD&#8221;) (NYSE: BDX), a leading global medical
technology company, from 2013 until 2018. While at BD, the company was selected as the Outstanding Corporate Innovator in 2015 by the
Product Development &amp; Management Association. Before joining BD, she served as Senior Vice President and Chief Medical Officer for
GlaxoSmithKline, plc (&#8220;GSK&#8221;) from 2008 to 2013, spending her last year at GSK as Senior Advisor to the CEO, leading GSK&#8217;s
Global Health Programs. Prior to 2008, Dr. Strahlman held senior executive leadership roles in global product development and commercialization
and business development at Pfizer, Inc., Novartis AG, Virogen Limited, and Merck &amp; Co., Inc. She was the Senior Vice President for
Research &amp; Development and Chief Medical Officer for Bausch &amp; Lomb from 1995 to 2000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Strahlman was chosen to serve as Industry
Representative on the FDA/CDER Dermatology and Ophthalmology Advisory Committee (DODAC), from 2008 to 2013. From 2016 to November 2020,
Dr. Strahlman served as a director of Syncona Limited (LSE: SYNC.L), having previously served as a director of Syncona Partners, LLP.
She is currently a director of Altria Group, Inc. (NYSE: MO). In addition to her corporate board service, Dr. Strahlman serves as a visiting
professor at the University of Turku in Finland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr. Strahlman earned a B.A. from Harvard University
in biochemistry and an M.D. from the Johns Hopkins School of Medicine. She is an American Board of Ophthalmology board-certified ophthalmologist,
having trained at the Wilmer Eye Institute from 1984 to 1987. She was awarded a Carnegie Mellon Public Health Fellowship in 1987, during
which she earned an M.H.Sc. in Epidemiology from the Bloomberg School of Public Health from 1987 to 1989.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Dr. Strahlman's extensive executive
experience in life science companies is valuable to the Company and qualifies her to serve as one of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Audit Committee and Audit Committee Financial Expert</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board of Directors has an Audit Committee,
composed of Michael Geltzeiler (Chair), Mr. Mather and Dr. Strahlman, each of whom satisfy the independence requirements of Rules 5605(a)(2)
and 5605(c)(2) of the Nasdaq listing rules and Section 10A(m)(3) of the Exchange Act. Our Board has determined that Mr. Geltzeiler is
an &#8220;audit committee financial expert&#8221; as defined in Item 407(d)(5)(ii) of Regulation S-K. Our Audit Committee met four times
during the 2023 fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Conduct</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have adopted a written code of business conduct
and ethics that applies to all of our directors, officers, and employees, including our principal executive officer, principal financial
officer, and principal accounting officer or controller, or persons performing similar functions, and agents and representatives. The
full text of our code of business conduct and ethics is available under the <i>Investors - Governance - Documents &amp; Charters </i>section
of our website at <i>www.eyenovia.com</i>. Our Board of Directors is responsible for overseeing our code of business conduct and ethics
and any waivers applicable to any director, executive officer, or employee. We intend to disclose future amendments to certain provisions
of our code of business conduct and ethics, or waivers of such provisions applicable to our directors, officers, and employees, including
our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions, and agents and representatives, on our website identified above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Hedging and Pledging Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under our Insider Trading Policy, we strongly
discourage our employees (including our named executive officers) and our directors from hedging our securities, holding shares of our
common stock in a margin account, or pledging shares of our common stock as collateral for a loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The following table sets forth information concerning
our executive officers as of April 16, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="white-space: nowrap; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Rowe</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Gandolfo</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Secretary</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bren Kern</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">See &#8220;<b>Directors</b>&#8221; above for additional
information about Mr. Rowe<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif"><b>John
Gandolfo</b></span> has been serving as our Chief Financial Officer and Secretary since December 2017. Mr. Gandolfo has approximately
35 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus
in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including
five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career.
Prior to joining Eyenovia, Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. (NYSE: XTNT) from July 2010 through
August 2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell Therapy, L.L.C., the global contract
development and manufacturing services platform of the Hitachi Chemical Co., Ltd. (now known as Showa Denko Materials, Co., Ltd.) Regenerative
Medicine Business Sector, represented in the United States by Hitachi Chemical Advanced Therapeutics Solutions, LLC (now known as Minaris
Regenerative Medicine, LLC), a manufacturer of stem cell therapies, from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo
served as the Chief Financial Officer of Power Medical Interventions, Inc. (acquired by Covidien Public Limited Company, which was in
turn acquired by Medtronic Public Limited Company (NYSE: MDT)), a publicly held developer and manufacturer of computerized surgical stapling
and cutter systems, from January 2007 to January 2009. Prior to joining Power Medical Interventions, Mr. Gandolfo was the Chief Financial
Officer of Bioject Medical Technologies Inc., a then publicly held supplier of needle-free drug delivery systems to the pharmaceutical
and biotechnology industries, from September 2001 to May 2006, and he served on the Bioject&#8217;s board of directors from September
2006 through May 2007. Prior to joining Bioject, Mr. Gandolfo was the Chief Financial Officer of Capital Access Network, Inc. (now known
as CAN Capital, Inc.), a privately held specialty finance company, from 2000 through September 2001, and Xceed Software, Inc. (OTC: EXDW),
an Internet consulting firm, from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer
of Impath, Inc., a then publicly held, cancer-focused healthcare information company. From 1987 through 1994, he was Chief Financial Officer
of Medical Resources, Inc., a then publicly held manager of diagnostic imaging centers throughout the United States. Mr. Gandolfo currently
serves on the board, compensation committee and audit committee of electroCore, Inc. (Nasdaq: ECOR) and on the board of Oragenics Inc.
(NYSE: OGEN). Mr. Gandolfo received his B.A. in business administration from Rutgers University. He is a certified public accountant (inactive
status) who began his professional career at Price Waterhouse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif"><b>Bren
Kern</b></span> has served as the Company&#8217;s Chief Operating Officer since January 2023. Prior to that, he served as the Company&#8217;s
Vice President of Manufacturing and Operations since June 2022. Previously, he was the Vice President of Manufacturing at Hound Labs,
Inc. from March 2021 to June 2023. He also served as the Vice President of Operations at Second Source Medical LLC from 2020 to 2021,
Biolux Research Ltd from 2019 to 2020 and BAROnova Inc. from 2016 to 2019. Mr. Kern earned his B.S. from the Oregon Institute of Technology
in 2003.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_003"></span>Item 11. Executive Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">This Item 11 discusses material
components of our executive compensation program for the following individuals, each of whom is one of our &#8220;named executive officers&#8221;
for 2023: Michael Rowe (our Chief Executive Officer), John P. Gandolfo (our Chief Financial Officer) and Bren Kern (our Chief Operating
Officer).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have opted to comply with the executive compensation
disclosure rules applicable to &#8220;smaller reporting companies&#8221;, as such term is defined in the rules promulgated under the Securities
Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key Elements of Our Compensation Program for 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2023, we compensated our named executive officers
through a combination of base salary and long-term equity incentives in the form of options. Our named executive officers are also eligible
for our standard benefits programs, which include group health insurance and vacation programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not use specific formulas or weightings
in determining the allocation of the various compensation elements. Instead, the compensation for our named executive officers has been
designed to provide a combination of fixed and at-risk compensation that is tied to the achievement of our short- and long-term objectives.
We believe that this approach achieves the primary objectives of our compensation program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are continually evaluating various compensation
programs to implement as our business evolves. The disclosures below describe our historical compensation practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth information regarding
compensation awarded to, earned by or paid to our named executive officers for fiscal years ended December 31, 2023 and 2022. The Company
does not have any non-equity incentive plans or awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and <br/>
Principal<br/>
Position</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/>
($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/>
($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Stock<br/>
    awards</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)<sup>(1)</sup></b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
awards <br/>
($)<sup>(1)</sup></b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All other<br/>
compensation<br/>
($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Michael Rowe</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2023</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;575,000</span></td>
    <td style="vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup>&#160;</span><span style="font-size: 10pt"></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">189,750</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">10,718</span></td>
    <td style="vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup>&#160;</span><span style="font-size: 10pt"></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">775,468</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><i>Chief Executive Officer</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">512,000</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">232,499</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">583,500</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">5,511</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">1,333,510</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">John P. Gandolfo</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;452,500</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">111,994</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">107,300</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">13,660</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">685,454</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><i>Chief Financial Officer</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">428,500</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">157,688</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">52,900</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(9)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">12,200</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(10)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">651,288</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Bren Kern</span><span style="font-size: 10pt; color: #231f20"><sup>(11)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">345,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(12)</sup>&#160;</span><span style="font-size: 10pt"></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">56,925</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">151,400</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(13)</sup>&#160;</span><span style="font-size: 10pt"></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">13,660</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(14)</sup>&#160;</span><span style="font-size: 10pt"></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">566,985</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><i>Chief Operating Officer</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The amounts reported in the &#8220;Stock awards&#8221; and &#8220;Option awards&#8221; columns reflect the aggregate fair value of stock-based compensation awarded during the year computed in accordance with the provisions of FASB ASC Topic 718. See Note 11 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 for the assumptions underlying the valuation of equity awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Mr. </span><span style="font-size: 10pt; color: #231f20">Rowe was paid pursuant to the terms of an Employment Agreement dated July 26, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents amounts paid to Mr. Rowe in 2023 for matching funds for his contributions to the Eyenovia 401(k) program and a monthly cell phone allowance received by all Eyenovia, Inc. employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">During 2022, we granted options to purchase 23,211 and 440,000 shares of common stock at an exercise price of $3.10 and $1.66, respectively, per share to Mr. Rowe. The options had grant date values of $52,900 and $530,600, respectively. The options vested as to one-third of the shares underlying the options on February 14, 2023 and August 1, 2023, respectively, and the remaining options become exercisable in 24 one-month anniversaries thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Represents amounts paid to Mr. Rowe in 2022 for matching funds for his contributions to the Eyenovia 401(k) program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Mr. </span><span style="font-size: 10pt; color: #231f20">Gandolfo was paid pursuant to the terms of an Employment Agreement dated February 15, &#160;2019, as amended on March 10, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2023, we granted options to purchase 68,235 shares of common stock at an exercise price of $2.16 per share to Mr. Gandolfo. The options had a grant date value of $107,300. The options vested as to one-third of the shares underlying the options on January 17, 2024 and the remaining options become exercisable in 24 one-month anniversaries thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents amounts paid to Mr. Gandolfo in 2023 for matching funds for his contributions to the Eyenovia 401(k) program, and a monthly cell phone allowance received by all Eyenovia, Inc. employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, we granted options to purchase 23,211 shares of common stock at an exercise price of $3.10 per share to Mr. Gandolfo. The options had a grant date value of $52,900. The options vested as to one-third of the shares underlying the options on February 14, 2023 and the remaining options become exercisable in 24 one-month anniversaries thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Represents amounts paid to Mr. Gandolfo in 2022 for matching funds for his contributions to the Eyenovia 401(k) program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Kern became a named executive officer for the first time for the fiscal year ended December 31, 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Mr. </span><span style="font-size: 10pt; color: #231f20">Kern was paid pursuant to the terms of an Employment Agreement dated December 19, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">During 2023, we granted </span><span style="font-size: 10pt; color: #231f20">options to purchase 120,000 shares of common stock at an exercise price of $1.72 per share to Mr. Kern. The options had a grant date value of $151,400. The options vested as to one-third of the shares underlying the options on January 3, 2024 and the remaining options become exercisable in 24 one-month anniversaries thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Represents amounts paid to Mr. Kern in 2023 for matching funds for his contributions to the Eyenovia 401(k) program, and a monthly cell phone allowance received by all Eyenovia, Inc. employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment and Consulting Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Michael Rowe</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Rowe is currently compensated for his services
as our Chief Executive Officer pursuant to an Employment Agreement dated July 26, 2022 (the &#8220;Rowe Employment Agreement&#8221;).
On July 26, 2022, the Board of Directors appointed Michael Rowe as the Company&#8217;s Chief Executive Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the Rowe Employment Agreement,
the Company must pay Mr. Rowe a base salary of not less than $575,000 per year. Mr. Rowe is eligible to receive an annual cash bonus based
upon the achievement of pre-established annual individual and Company objectives determined by the Company&#8217;s Board of Directors
or its Compensation Committee. He is also eligible to receive equity award grants pursuant to the terms and conditions of the Company&#8217;s
then current equity plan, subject to the terms of an equity agreement as approved by the Board of Directors or Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>John P. Gandolfo</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Gandolfo is currently compensated for his
services as our Chief Financial Officer pursuant to an Employment Agreement dated February 15, 2019, as amended on March 10, 2022 (the
 &#8220;Gandolfo Employment Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the Gandolfo Employment Agreement,
the Company must pay Mr. Gandolfo a base salary of not less than $366,000 per year. Mr. Gandolfo is eligible to receive an annual cash
bonus, based upon the achievement of pre-established annual individual and Company objectives determined by the Company&#8217;s Board
of Directors or its Compensation Committee. He also is eligible to receive equity award grants pursuant to the terms and conditions of
the Company&#8217;s then current equity plan, subject to the terms of an equity agreement as approved by the Board of Directors or Compensation
Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Bren Kern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Mr. Kern is currently compensated for his services
as our Chief Operating Officer pursuant to an Employment Agreement dated December 19, 2022 (the &#8220;Kern Employment Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Under the terms of the Kern Employment Agreement,
the Company must pay Mr. Kern a base salary of not less than $345,000 per year. Mr. Kern is eligible to receive an annual cash bonus,
based upon the achievement of pre-established annual individual and Company objectives determined by the Company&#8217;s Board of Directors
or its Compensation Committee. He is also eligible to receive equity award grants pursuant to the terms and conditions of the Company&#8217;s
then current equity plan, subject to the terms of an equity agreement as approved by the Board of Directors or Compensation Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Termination of Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Rowe Employment Agreement discussed above
provides the following upon termination of Mr. Rowe&#8217;s employment:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Termination
by Company for Cause; by Company without Cause or by Executive without Good Reason within Executive&#8217;s First Six (6) Months of Employment;
or as a Result of Executive&#8217;s Disability or Death</i></span>. If Mr. Rowe&#8217;s employment is terminated by us for Cause (as defined
in the Rowe Employment Agreement), by us without Cause within Mr. Rowe&#8217;s first six months of employment, by Mr. Rowe without Good
Reason (as defined in the Rowe Employment Agreement), or as a result of Mr. Rowe&#8217;s Disability (as defined in the Rowe Employment
Agreement) or death, then we must pay the portion of Mr. Rowe&#8217;s base salary that has accrued prior to such termination and has not
yet been paid, any bonus previously earned by Mr. Rowe but not yet paid, any accrued and unused vacation or sick leave, and the amount
of any expenses properly incurred by Mr. Rowe prior to any such termination and not yet reimbursed (collectively, the &#8220;Rowe Accrued
Obligations&#8221;) promptly following the effective date of such termination, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Termination
by Company without Cause or by Executive for Good Reason Following Executive&#8217;s First Six Months of Employment</i></span>. In the
event that Mr. Rowe&#8217;s employment is terminated by us other than for Cause, Disability or death at any time after Mr. Rowe&#8217;s
first six months of employment as CEO, then, in addition to the Rowe Accrued Obligations, Mr. Rowe shall receive the following, subject
to certain terms and conditions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Severance Payment</i></span><span style="font-size: 10pt">. Payment in an amount equal to Mr. Rowe&#8217;s base salary for a 12-month period, less customary and required taxes and employment-related deductions, paid in one lump sum amount.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Benefits</i></span><span style="font-size: 10pt">. health insurance coverage at no cost to Mr. Rowe, until the earlier to occur of 12 months following the termination date or the date Mr. Rowe elects to participate in the group health plan of another employer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Gandolfo Employment Agreement discussed above
provides that if Mr. Gandolfo&#8217;s employment is terminated by the Company without &#8220;Cause&#8221; (as defined in the Company&#8217;s
2018 Omnibus Stock Incentive Plan (the &#8220;2018 Plan&#8221;)) or Mr. Gandolfo suffers an &#8220;Involuntarily Termination&#8221; (as
defined in the Gandolfo Employment Agreement) provided that Mr. Gandolfo has signed a full release of all claims, Mr. Gandolfo will be
entitled to receive: (i) severance pay equal to 12 months of his then-current base salary, and (ii) a reimbursement for health insurance
benefits under COBRA for Mr. Gandolfo and his spouse and dependents for a period of 12 months or until Mr. Gandolfo becomes eligible
for comparable insurance benefits from another employer, whichever is earlier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As defined in the 2018 Plan, &#8220;Cause&#8221;
means, with respect to the termination by the Company or a Related Entity of a Grantee&#8217;s Continuous Service: (i) that such termination
is for &#8220;Cause&#8221; as such term (or word of like import) is expressly defined in a then-effective written employment agreement,
consulting agreement, service agreement or other similar agreement between the Grantee and the Company or such Related Entity, provided,
however, that with regard to any agreement that defines &#8220;Cause&#8221; on the occurrence of or in connection with a Corporate Transaction,
such definition of &#8220;Cause&#8221; shall not apply until a Corporate Transaction actually occurs; or (ii) in the absence of such then-effective
written agreement and definition, is based on, in the determination of the Administrator: (A) the Grantee&#8217;s performance of any act,
or failure to perform any act, in bad faith and to the detriment of the Company or a Related Entity; (B) the Grantee&#8217;s dishonesty,
intentional misconduct or material breach of any agreement with the Company or a Related Entity; (C) the Grantee&#8217;s material breach
of any noncompetition, confidentiality or similar agreement with the Company or a Related Entity, as determined under such agreement;
(D) the Grantee&#8217;s commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person; (E)
if the Grantee is an Employee or Consultant, the Grantee&#8217;s engaging in acts or omissions constituting gross negligence, misconduct
or a willful violation of a Company or a Related Entity policy which is or is reasonably expected to be materially injurious to the Company
and/or a Related Entity; or (F) if the Grantee is an Employee, the Grantee&#8217;s failure to follow the reasonable instructions of the
Board or such Grantee&#8217;s direct supervisor, which failure, if curable, is not cured within 10 days after notice to such Grantee or,
if cured, recurs within 180 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As defined in the Gandolfo Employment Agreement,
 &#8220;Involuntary Termination&#8221; means the occurrence of any of the following without the written consent of Mr. Gandolfo: (i) a
material diminution in Mr. Gandolfo&#8217;s Base Salary, Bonus target or benefits (other than a material diminution that is applicable
to all similarly situated employees and executives of the Company in connection with an across-the-board cost savings strategy); (ii)
a material diminution in Mr. Gandollfo&#8217;s authority, duties or responsibilities; (iii) a material diminution in the level of Mr.
Gandolfo&#8217;s reporting structure, including a requirement that Mr. Gandolfo report to a corporate officer or employee instead of reporting
directly to the CEO; or (iv) any other action or inaction that constitutes a material breach by the Company of the Gandolfo Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Kern Employment Agreement discussed above
provides the following upon termination of Mr. Kern&#8217;s employment:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Termination
by Company for Cause; by Company without Cause or by Executive without Good Reason within Executive&#8217;s First Six Months of Employment;
or as a Result of Executive&#8217;s Disability or Death</i></span>. If Mr. Kern&#8217;s employment is terminated by us for Cause (as defined
in the Kern Employment Agreement), by us without Cause within Mr. Kern&#8217;s first six months of employment, by Mr. Kern without Good
Reason (as defined in the Kern Employment Agreement), or as a result of Mr. Kern&#8217;s Disability (as defined in the Kern Employment
Agreement) or death, then we must pay the portion of Mr. Kern&#8217;s base salary that has accrued prior to such termination and has not
yet been paid, any accrued and unused vacation or sick leave, and the amount of any expenses properly incurred by Mr. Kern prior to any
such termination and not yet reimbursed (collectively, the &#8220;Kern Accrued Obligations&#8221;) promptly following the effective date
of such termination, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Termination
by Company without Cause or by Executive for Good Reason Following Executive&#8217;s First Six Months of Employment</i></span>. In the
event that Mr. Kern&#8217;s employment is terminated by us other than for Cause, Disability or death or by Mr. Kern for Good Reason at
any time after Mr. Kern&#8217;s first six months of employment as our Chief Operating Officer, then, in addition to the Kern Accrued Obligations,
Mr. Kern will receive the following, subject to certain terms and conditions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#8226;</span></td><td style="padding-right: 73pt"><i>Severance Payment</i>. Payment in an amount equal to Mr. Kern&#8217;s base salary for a 12-month period,
less customary and required taxes and employment-related deductions, paid in one lump sum amount.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#8226;</span></td><td><i>Benefits</i>. Health insurance coverage at no cost to Mr. Kern, until the earlier to occur of 12 months following the termination
date or the date Mr. Kern elects to participate in the group health plan of another employer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Change in Control Provision of Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Rowe Employment Agreement and the Gandolfo
Employment Agreement also provide that if within 12 months following any &#8220;Corporate Transaction&#8221; (as defined in the 2018 Plan)
of the Company, the executive&#8217;s employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination
(as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be
entitled to receive, in lieu of what is described above: (i) severance pay equal to 12 months of his then-current base salary, and (ii)
a reimbursement for health insurance benefits under COBRA for the executive and his spouse and dependents for a period of 12 months or
until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As defined in the 2018 Plan, a &#8220;Corporate
Transaction&#8221; means any of the following transactions, provided, however, that the Administrator shall determine under parts (iv)
and (v) whether multiple transactions are related, and its determination shall be final, binding and conclusive: (i) a merger or consolidation
in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which
the Company is incorporated; (ii) the sale, transfer or other disposition of all or substantially all of the assets of the Company; (iii)
the complete liquidation or dissolution of the Company; (iv) any reverse merger or series of related transactions culminating in a reverse
merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A)
the Shares outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether
in the form of securities, cash or otherwise, or (B) in which securities possessing more than 50% of the total combined voting power of
the Company&#8217;s outstanding securities are transferred to a person or persons different from those who held such securities immediately
prior to such merger or the initial transaction culminating in such merger; or (v) acquisition in a single or series of related transactions
by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership
(within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than 50% of the total combined voting power of the
Company&#8217;s outstanding securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Kern Employment Agreement provides that if,
within a period of 30 days prior to or 12 months following a Change of Control of the Company, Mr. Kern&#8217;s employment is terminated
by the Company without Cause or by Mr. Kern for Good Reason, provided that Mr. Kern has signed a separation agreement including a full
release of all claims, Mr. Kern will be entitled to receive, in lieu of what is described above: (i) severance pay equal to 12 months
of his then-current base salary, and (ii) medical insurance coverage at no cost for a period of 12 months or until Kern elects to participate
in the group health plan of another employer, whichever is earlier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As defined in the Kern Employment Agreement, a
 &#8220;Change of Control&#8221; means the occurrence of any of the following events: (i) a merger or consolidation of Company, whether
or not approved by the Board, other than a merger or consolidation which would result in the voting securities of Company outstanding
immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or the parent of such entity) more than 50% of the total voting power represented by the voting securities of Company
or such surviving entity or parent of such entity, as the case may be, outstanding immediately after such merger or consolidation; (ii)
the acquisition of more than 50% of the voting power of the outstanding securities of the Company by one or more other entities, unless
the Company&#8217;s stockholders of record immediately prior to such acquisition will, immediately after such acquisition, hold at least
50% of the voting power of the Company, provided that a bona fide equity financing that the Board approves does not constitute a Change
of Control; or (iii) the sale or disposition by Company of all or substantially all of Company&#8217;s assets in a transaction requiring
Board approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards as of December 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth information regarding
all outstanding stock options held by our named executive officers as of December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of <br/>
securities<br/>
underlying<br/>
unexercised<br/>
options (#)</b></span> <span style="font-size: 10pt"><br/>
<b>exercisable</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center"><sup>&#160;</sup>&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
securities<br/>
underlying<br/>
unexercised<br/>
options (#)<br/>
unexercisable</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center"><sup>&#160;</sup>&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
exercise<br/>
price<br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
expiration<br/>
date</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Michael Rowe</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">60,000</span></td>
    <td style="vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup>&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom; width: 3%"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">6.30</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">07/02/2028</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20"><i>Chief Executive Officer</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">19,874</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">6.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">07/24/2028</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">42,722</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3.11</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">08/16/2029</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">141,622</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">06/03/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">124,692</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3,566</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)&#160;</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">6.01</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">01/29/2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">14,184</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">9,027 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)&#160;</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3.10</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">02/14/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">195,554</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">244,446</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">1.66</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">08/01/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Gandolfo</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,200</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.72</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/16/2028</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,842</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.20</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/24/2028</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,402</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2029</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">114,774</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#8212;</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/30/2030</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">124,692</span><span style="font-size: 10pt"></span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3,566</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/29/2031</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">14,184</span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">9,027</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2032</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><sup>&#160;</sup>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,235</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(9)</sup>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/17/2033</span></td>
    <td>&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bren Kern</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">22,222</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,778</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">1.66</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">08/01/2032</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Operating Officer</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#8212;</span></td>
    <td style="vertical-align: bottom"><sup>&#160;</sup>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(10)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">1.72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">01/03/2033</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to 1,666 shares on August 2, 2018 and vested in equal 1,666 share amounts on each of the 35 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on July 24, 2019 and became exercisable in equal share amounts on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the option on August 16, 2020 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on June 3, 2021 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on January 30, 2022 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on February 14, 2023 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on August 1, 2023 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to 1,977 shares on May 16, 2018 and vested in equal 1,977 share amounts on each of the 35 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on January 17, 2024 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The options vested as to one-third of the shares underlying the options on January 3, 2024 and the remaining options become exercisable in equal increments on each of the 24 one-month anniversaries thereafter, subject to acceleration in certain circumstances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2022, our Board of Directors, upon recommendation
of the Compensation Committee, adopted a Non-Employee Director Compensation Policy for the Company&#8217;s non-employee directors, which
was further amended in August 2022 and in March 2023. Each such non-employee director receives an annual retainer of $40,000 and an equity
award valued at $80,000 payable half in RSUs and half in options for service on the Board. The settlement of the RSUs is deferred until
such non-employee director ceases to serve on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, our Audit Committee Chair receives
an additional annual retainer of $20,000, while all other members of our Audit Committee received an additional annual retainer of $10,000.
Our Compensation Committee Chair received an additional annual retainer of $15,000, while all other members of our Compensation Committee
received an additional annual retainer of $7,500. Our Nominating and Corporate Governance Committee Chair received an additional annual
retainer of $10,000, while all other members of our Nominating and Corporate Governance Committee received an additional annual retainer
of $5,000. Our Innovation Committee Chair received an additional annual retainer of $15,000, while all other members of our Innovation
Committee received an additional annual retainer of $7,500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth certain information
concerning the compensation of our then serving directors (excluding Mr. Rowe who was a named executive officer) for the fiscal year ended
December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees earned<br/>
or paid in<br/>
cash<br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br/>
awards<br/>
($)<sup>(1)</sup></b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
awards<br/>
($)<sup>(1)</sup></b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All other<br/>
compensation<br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev, M.D., M.P.H<sup>(2)</sup>&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">107,500</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">40,000</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">247,500</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Stephen Benjamin<sup>(3)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;13,750</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;&#160;&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;&#160;&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;13,750</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Michael Geltzeiler<sup>(4)</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;&#160;&#160;7,826</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">24,800</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,200</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(9)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;57,826</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Rachel Jacobson</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;65,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">145,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Charles E. Mather IV</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;68,750</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">148,750</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Ram Palanki, Pharm.D</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;60,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)&#160;</sup>&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)&#160;</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">140,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Ellen Strahlman, M.D.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">&#160;&#160;82,500</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">162,500</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td colspan="20">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">The amounts reported in the &#8220;Stock awards&#8221; and &#8220;Option awards&#8221; columns reflect the aggregate fair value of stock-based compensation awarded during the year computed in accordance with the provisions of FASB ASC Topic 718. See Note 11 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 for the assumptions underlying the valuation of equity awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective August 1, 2022, Dr. Ianchulev became Executive Chair of the Board and receives $15,000 per quarter for his services as the Executive Chair in addition to the compensation payable to non-employee members of the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Mr. Benjamin resigned from the Board on February 28, 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Mr. Geltzeiler was appointed to the Board on November 10, 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2023, the Board of Directors granted to each of Dr. Ianchulev, Ms. Jacobson, Mr. &#160;Mather, Dr. Palanki and Dr. Strahlman 17,424 RSUs with an aggregate grant date fair value of $40,000, computed in accordance with FASB ASC Topic 718. These RSUs will vest on the earlier of June 27, 2024 or the date of the Company&#8217;s 2024 annual meeting of stockholders (the &#8220;2024 Annual Meeting&#8221;), subject to the director&#8217;s continued service on the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2023, the Board of Directors granted to each of Dr. Ianchulev, Ms. Jacobson, Mr. Mather, Mr. Palanki and Dr. Strahlman options to purchase 24,691 shares of our common stock at an exercise price of $2.32 per share, exercisable on the earlier of June 27, 2024 or the date of the 2024 Annual Meeting, subject to the director&#8217;s continued service on the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective August 1, 2022, Dr. Ianchulev became Executive Chair of the Board and receives $15,000 per quarter for Medical Advisory services in addition to the compensation payable as the Executive Chair as well as the compensation payable to non-employee members of the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 14, 2023, the Board of Directors approved granted to Mr. Geltzeiler 19,814 RSUs with an aggregate grant date fair value of $24,800, computed in accordance with FASB ASC Topic 718. These RSUs will vest on the earlier of June 27, 2024 or the date of the 2024 Annual Meeting, subject to Mr. Geltzeiler&#8217;s continued service on the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 14, 2023, the Board of Directors granted to Michael Geltzeiler options to purchase 28,799 shares of our common stock at an exercise price of $1.25 per share, exercisable on the earlier of June 27, 2024 or the date of the 2024 Annual Meeting, subject to Mr. Geltzeiler&#8217;s continued service on the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None of our non-employee directors received any
compensation for the fiscal year ended December 31, 2023 in their capacity as directors other than as reflected above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_004"></span>Item 12.&#160;&#160;Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table provides information as of
December 31, 2023 about our common stock that may be issued upon the exercise of options, warrants and rights under all of our existing
equity compensation plans (including individual arrangements):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Equity Compensation Plan Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of&#160;securities</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of securities</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise&#160;price</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>remaining&#160;available&#160;for</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to&#160;be issued&#160;upon</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of&#160;outstanding</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>future&#160;issuance&#160;under</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise&#160;of</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options,</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>equity&#160;compensation plans</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding options,</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants&#160;and</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(excluding securities</b></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan Category</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrants, and&#160;rights</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>rights</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>reflected&#160;in column&#160;(a))</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014 Equity Incentive Plan, as amended</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">851,610</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,625</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated 2018 Omnibus Stock Incentive Plan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,696,531</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,871,784</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,548,141</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,054,409</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth certain information
regarding the beneficial ownership of our common stock as of April 16, 2024, unless otherwise noted below, for the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person or entity known to own beneficially more than 5% of our outstanding common stock as of the date indicated in the corresponding footnote;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the named executive officers set forth in the Summary Compensation Table;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each director; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all current directors and executive officers as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Applicable percentage ownership is based on 50,957,869
shares of our common stock outstanding as of April 16, 2024, unless otherwise noted below. Beneficial ownership is determined in accordance
with the rules of the SEC, based on factors including voting and investment power with respect to shares. Common stock subject to options
currently exercisable, or exercisable within 60 days after April 16, 2024 is deemed outstanding for the purpose of computing the percentage
ownership of the person holding those securities, but are not deemed outstanding for computing the percentage ownership of any other person.
Unless otherwise indicated, the address for each listed stockholder is c/o Eyenovia, Inc., 295 Madison Avenue, Suite 2400, New York, NY
10017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; float: right; width: 94%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Beneficial Owner</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares <br/>
Beneficially <br/>
Owned Number</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors and Named Executive Officers</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; width: 73%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Rowe<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">676,607</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td>
    <td style="vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Gandolfo<sup>(2)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">443,774 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bren Kern<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">86,944 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev<sup>(4)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">2,078,437</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Geltzeiler</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">48,613</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rachel Jacobson<sup>(5)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">102,957</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles E. Mather IV<sup>(6)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">183,240</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Palanki<sup>(7)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">90,322</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen Strahlman<sup>(8)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">128,007 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All directors and executive officers as a group (9 persons)<sup>(9)</sup></i></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">3,838,901</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>5% Stockholders:</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stuart Grant<sup>(10)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,108,145</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.0</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Armistice Capital, LLC</span><span style="font-size: 10pt"><sup>(11)</sup></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">4,378,000</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div style="clear: both"></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1% of the outstanding shares of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(1)</td><td>Includes (i) 32,927 shares of common stock and (ii) 643,680 shares of common stock underlying options that are exercisable within
60 days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(2)</td><td>Includes (i) 8,000 shares of common stock and (ii) 435,774 shares of common stock underlying options that are exercisable within 60
days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(3)</td><td>Includes (i) 2,500 shares of common stock and (ii) 84,444 shares of common stock underlying options that are exercisable within 60
days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(4)</td><td>Includes (i) 309,895 shares of common stock, (ii) 1,055,495 shares of common stock underlying options that are exercisable within
60 days of April 16, 2024, (iii) 38,557 RSUs, (iv) 61,823 shares underlying warrants held by Dr. Ianchulev directly that are exercisable
within 60 days of April 16, 2024, (v) 606,667 shares of common stock held by PME and (vi) 6,000 shares of common stock held by The Meliora
Trust . Dr. Ianchulev is one of the two principal shareholders of PME and therefore may be deemed to have beneficial ownership of the
shares of common stock held by PME.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(5)</td><td>Includes (i) 42,752 RSUs that vest within 60 days of April 16, 2024, and (ii) 60,205 shares of common stock underlying options that
are exercisable within 60 days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(6)</td><td>Includes (i) 29,000 shares of common stock, (ii) 65,785 RSUs that vest within 60 days of April 16, 2024, and (iii) 88,455 shares of
common stock underlying options that are exercisable within 60 days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(7)</td><td>Includes (i) 37,428 RSUs that vest within 60 days of April 16, 2024, and (ii) 52,895 shares of common stock underlying options that
are exercisable within 60 days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(8)</td><td>Includes (i) 37,685 shares of common stock, (ii) 37,428 RSUs that vest within 60 days of April 16, 2024, and (iii) 52,894 shares of
common stock underlying options that are exercisable within 60 days of April 16, 2024.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(9)</td><td>See footnotes (1) through (8).</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(10)</td><td>Based on a Form 4 filed with the SEC on March 28, 2024, and subsequent reports filed pursuant to Section 16 of the Exchange Act by
Mr. Grant. Includes (i) 5,430,715 shares of common stock and (ii) 677,430 shares of common stock underlying warrants that are exercisable
within 60 days of April 16, 2024. Mr. Grant&#8217;s address is 11 Summit Lane, Greenville, Delaware 19807.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(11)</td><td>Based on information known to the Company and a Schedule 13G filed with the SEC on February 14, 2024 by Armistice Capital, LLC (&#8220;Armistice
Capital&#8221;). Consists of 4,378,000 shares of common stock (the &#8220;Shares&#8221;) and excludes 9,708,839 shares of common stock
underlying warrants (the &#8220;Warrants&#8221;) that are exercisable within 60 days of April 16, 2024. The Warrants are only exercisable
to the extent that the holder thereof, together with its affiliates, would beneficially own no more than 4.99% of the outstanding shares
of our common stock after giving effect to such exercise (the &#8220;Warrant Beneficial Ownership Limitation&#8221;). As a result of the
Warrant Beneficial Ownership Limitation, the number of shares that may be issued to the holder upon exercise of the Warrants may change
depending upon changes in the outstanding shares of our common stock. Upon 61 days&#8217; prior notice to the Company, the holder may
increase, decrease or terminate the Warrant Beneficial Ownership Limitation. Armistice Capital is the investment manager of Armistice
Capital Master Fund Ltd. (the &#8220;Master Fund&#8221;), the direct holder of the Shares and the Warrants, and pursuant to an Investment
Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Company held by the Master Fund
and thus may be deemed to beneficially own the securities of the Company held by the Master Fund. Steven Boyd, as the managing member
of Armistice Capital, may be deemed to beneficially own the securities of the Company held by the Master Fund. The Master Fund specifically
disclaims beneficial ownership of the securities of the Company directly held by it by virtue of its inability to vote or dispose of such
securities as a result of its Investment Management Agreement with Armistice Capital. The address of Armistice Capital, LLC and Mr. Boyd
is 510 Madison Avenue, 7<sup>th</sup> Floor, New York, New York, 10022.&#160;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_005"></span>Item 13.&#160;&#160;Certain Relationships and Related Transactions,
and Director Independence.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Below are transactions since January 1, 2022 to
which we have been or are a participant, including currently proposed transactions, in which the amount involved in the transaction exceeds
$120,000 and in which any of our directors, executive officers, or beneficial holders of more than 5% of any class of our capital stock,
or any immediate family member of, or person sharing the household with any of these individuals, had or has a direct or indirect material
interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License Agreement with Senju Pharmaceutical Co., Ltd.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2015, the Company entered into an exclusive
license agreement with Senju (the &#8220;Senju License Agreement&#8221;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing
license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell,
and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia 5% royalties
on sales (net of certain manufacturing costs) for the term of the Senju License Agreement, subject to certain adjustments upon the loss
of patent coverage for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country
basis, until the latest to occur of: (i) the tenth anniversary of the first commercial sale of such a product candidate in a country;
or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there have been no commercial sales of such
a product in Asia; therefore, no royalties have been earned. Senju is owned by the family of a former member of the Company&#8217;s Board
of Directors and, together, they beneficially owned greater than 5% of the Company&#8217;s common stock during a portion of the
fiscal year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 8, 2020, Eyenovia entered into an amendment
(the &#8220;Senju License Amendment&#8221;) to the Senju License Agreement. Pursuant to the Senju License Amendment, the Company can license
to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &#8220;Senju
Licensed Products&#8221;) previously licensed to Senju in China (including the People&#8217;s Republic of China, Hong Kong, Macao, and
Taiwan) and South Korea (the &#8220;Territory&#8221;) in the agreement executed by the Company on April 8, 2021. The Senju Licensed Products
are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia
in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Senju License Amendment, the Company
must pay Senju (a) a percentage in the range of 30 to 40 percent of revenue on any lump-sum payments the Company receives from the third
party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory,
and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory,
the aggregate of which must be at least a $9 million minimum payment to Senju; and (b) a percentage in the range of 30 to 40 percent of
any sales royalty revenue the Company receives from the third party. Since the Company executed a third-party license prior to April 8,
2021, the License Amendment will remain in effect for the duration of the license, subject to early termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Senju License Agreement was further amended
in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &#8220;Letter Agreement&#8221;). Pursuant to the Letter
Agreement, the Company will pay a percentage in the range of 30 to 40 percent of certain payments, royalties, or net proceeds received
from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. The Senju License Agreement was amended further by
the License Amendment 2, effective September 14, 2021 (&#8220;Amendment 2&#8221;). The Amendment 2 excludes Greater China and South Korea
from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion,
and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license
revenue and sales revenue, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a one-time upfront payment of $250,000, paid on September 17, 2021, which represented an inducement to Senju to approve Amendment 1 of the Arctic Vision License Agreement related to the MicroStat product;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a percentage in the range from thirty percent to forty percent of any upfront or milestone lump sum payments, or net revenues received by the Company in connection with any licensed product using piezo-print technology in a microdose dispenser containing: (a) the chemical substance atropine sulfate as its sole active ingredient and that is used for the treatment of myopia in humans; (b) the chemical substance pilocarpine as its sole active ingredient and that is used for the treatment of presbyopia in humans; or (c) the chemical substances phenylephrine and tropicamide in combination as active ingredients that are used for pharmaceutical mydriasis in humans (the &#8220;LA2 Licensed Product&#8221;) from certain third parties; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a percentage in the range from thirty to forty percent of the amounts received by the Company in connection with sales of the LA2 Licensed Product in China and South Korea by certain third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our third amended and restated certificate of
incorporation, as amended, and our second amended and restated bylaws provide that we shall indemnify our directors and officers to the
fullest extent permitted by law. We also maintain a directors&#8217; and officers&#8217; liability insurance policy. The policy insures
directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and
reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions.
We have also entered into director indemnification agreements with each of our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment and Consulting Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into employment and consulting
arrangements with our named executive officers that provide for salary and severance compensation. For more information regarding these
arrangements and amounts earned pursuant to them, see &#8220;<i>Executive Compensation&#8201;-&#8201;Employment and Consulting Arrangements</i>&#8221;
and the &#8220;<i>Summary Compensation Table</i>&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Issued to Executive Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We granted options and restricted stock units
to our named executive officers and directors in 2023, as more fully described in the sections entitled &#8220;<i>Outstanding Equity Awards
as of December 31, 2023</i>&#8221; and &#8220;<i>Director Compensation</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Agreement with Stuart Grant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, the Company entered into
a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Stuart M. Grant, a greater-than-5% stockholder of the Company. Pursuant
to the Settlement Agreement, our Board of Directors appointed two new directors, Rachel Jacobson and Stephen Benjamin, to the Board to
fill the vacancies on the Board at such time. Ms. Jacobson and Mr. Benjamin were nominated as directors at the 2022 annual meeting of
stockholders and elected as directors at such meeting; Mr. Benjamin has since resigned from the Board to take a position at the White
House. The Board of Directors has nominated Ms. Jacobson for re-election at the 2024 Annual Meeting. The Settlement Agreement has expired
and is no longer in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Procedures for Approval of Related-Party Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee, pursuant to its written charter
and our Related Party Transaction Policy, is responsible for reviewing and approving or ratifying any related-party transaction reaching
a certain threshold of significance. In the course of its review and approval or ratification of a related-party transaction, the committee,
among other things, considers, consistent with Item 404 of Regulation S-K, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction was undertaken in the ordinary course of business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction was initiated by the Company or the related person;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the terms of the transaction are fair to the Company and on the same basis as would apply if the transaction did not involve the related person;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether there are business reasons for the Company to enter into the transaction;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approximate dollar value of the transaction, and the significance of that amount, particularly as it relates to the related person;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction would impair the independence of an outside director;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any pre-existing contractual obligations; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction would present an improper conflict of interest for any director or executive officer of the Company, taking into account the size of the transaction, the overall financial position of the director, executive officer, or the related person, the direct or indirect nature of the director&#8217;s, executive officer&#8217;s, or the related person&#8217;s interest in the transaction and the ongoing nature of any proposed relationship, and any other factors the Audit Committee deems relevant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any member of the Audit Committee who is a related
person with respect to a transaction under review will not be permitted to vote or participate in discussions regarding approval or ratification
of the transaction, but must provide all material information regarding the transaction to the Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Future transactions between us and our officers,
directors, or 5% stockholders, and respective affiliates will be on terms that the committee determines in good faith to be in the best
interests of the Company and its stockholders and will be approved by a majority of our directors who do not have an interest in the transactions
and who had access, at our expense, to our legal counsel or independent legal counsel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To the best of our knowledge, since January 1,
2022, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently proposed
transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds $120,000,
and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5%
of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation
to our officers and directors in the ordinary course of business).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27.8pt">Our Board of Directors has
reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested
from and provided by each director concerning his background, employment and affiliations, including family relationships, our Board of
Directors has determined that each of our directors, with the exception of Dr. Ianchulev and Mr. Rowe, is an &#8220;independent director&#8221;
as defined under Rule 5606(a)(2) of the Nasdaq Listing Rules. Our Board of Directors determined that Drs. Strahlman and Palanki, Messrs.
Geltzeiler and Mather, and Ms. Jacobson satisfy the applicable independence standards established by the SEC and the Nasdaq Listing Rules.
In making such determinations, our Board of Directors considered the relationships that each non-employee director has with our Company
and all other facts and circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership
of our capital stock by each non-employee director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_006"></span>Item 14.&#160;&#160;Principal Accountant Fees and Services.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee has adopted a policy for the
pre-approval of all audit and permitted non-audit services that may be performed by our independent registered public accounting firm.
Under this policy, each year, at the time it engages an independent registered public accounting firm, the Audit Committee pre-approves
the engagement terms and fees and may also pre-approve detailed types of audit-related and permitted non-audit services, subject to certain
dollar limits, to be performed during the year. All other permitted non-audit services are required to be pre-approved by the Audit Committee
on an engagement-by-engagement basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the aggregate fees
billed for professional services rendered to us by Marcum in 2023 and 2022. A description of these various fees and services follows the
table.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">Audit Fees</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: #231f20">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #231f20; text-align: right">241,610</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: #231f20">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #231f20; text-align: right">162,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #231f20; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit-Related Fees</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">155,970</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">87,575</td><td style="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax Fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">All Other Fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Audit Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Audit fees relate to the financial statement audits,
the quarterly reviews and related matters. Audit fees include services rendered by Marcum for the 2023 and 2022 audits totaling $167,375 and $96,200 respectively. Fees also include services rendered by Marcum for their reviews of the condensed financial statements included
in the Company&#8217;s Forms 10-Q during the first three quarters of 2023 and 2022 totaling $74,235 and $66,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Audit-Related Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Audit-related fees include services, including
services related to the review of our registration statements, SEC comment letters and issuance of comfort letters by Marcum LLP, in 2023
and 2022, totaling $155,970 and $87,575, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Tax Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No tax fees were billed to us by Marcum for the
years ended December 31, 2023 or 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>All Other Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No other fees were billed to us by Marcum for
the years ended December 31, 2023 or 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_007"></span>PART&#160;IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="toc_008"></span>Item&#160;15.&#160;&#160;&#160;Exhibits, Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Exhibit&#160;Index</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a list of exhibits filed as part of this Annual Report
on Form&#160;10-K/A:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left; vertical-align: bottom">Incorporated&#160;by&#160;Reference&#160;from&#160;Filings&#160;as&#160;Noted&#160;Below
    (Unless Otherwise Indicated)</td></tr>
<tr>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 12%">Exhibit<br/>
    Number</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 34%">Exhibit Description</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 10%">Form</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 10%">File No.</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 10%">Exhibit</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 14%">Filing Date</td></tr>

<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm"><span style="color: #0000ee">Third Amended and Restated Certificate of Incorporation</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 29, 2018</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm"><span style="color: #0000ee">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2018</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922012277/tm225598d1_ex3-1.htm"><span style="color: #0000ee">Second Amended and Restated Bylaws</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 7, 2022</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex4d1.htm"><span style="color: #0000ee">Description of Securities</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm"><span style="color: #0000ee">Form of Class A Warrant Issued on March 24, 2020</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2020</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm"><span style="color: #0000ee">Form of Class B Warrant Issued on March 24, 2020</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2020</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921063815/tm2115655d1_ex4-1.htm"><span style="color: #0000ee">Form of Warrant Issued on May 7, 2021</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 10, 2021</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922031848/tm228760d1_ex4-1.htm"><span style="color: #0000ee">Form of Pre-Funded Warrant Issued on March 7, 2022</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 9, 2022</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922031848/tm228760d1_ex4-2.htm"><span style="color: #0000ee">Form of Warrant Issued on March 7, 2022</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 9, 2022</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span><span style="font-size: 10pt">.7</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/tm2324923d1_ex4-1.htm"><span style="color: #0000ee">Form of Warrant Issued on August 29, 2023</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span><span style="font-size: 10pt">.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 29, 2023</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/tm2324923d1_ex4-2.htm"><span style="color: #0000ee">Form of Warrant issued on August 29, 2023</span></a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 29, 2023</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm"><span style="color: #0000ee">Exclusive License Agreement, dated March 18, 2015, between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd.</span></a></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm"><span style="color: #0000ee">Amendment to the Exclusive License Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated April 8, 2020</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm"><span style="color: #0000ee">Letter Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated August 10, 2020</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm"><span style="color: #0000ee">Master Consulting Services Agreement, dated November 4, 2014, between Eyenovia, Inc. and Private Medical Equity, Inc.</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm"><span style="color: #0000ee">Executive Employment Agreement, dated February 15, 2019, by and between the Company and Tsontcho Ianchulev</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm"><span style="color: #0000ee">Executive Employment Agreement, dated February 15, 2019, by and between the Company and John Gandolfo</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm"><span style="color: #0000ee">Executive Employment Agreement, dated February 15, 2019, by and between the Company and John Gandolfo</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm"><span style="color: #0000ee">Form of Nondisclosure, Assignment of Inventions and Noncompetition Agreement</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm"><span style="color: #0000ee">Eyenovia, Inc. 2014 Equity Incentive Plan, as amended</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-233278</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm"><span style="color: #0000ee">Form of Nonqualified Stock Option Agreement</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-233278</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm"><span style="color: #0000ee">Registration Rights Agreement, dated March 23, 2020, between Eyenovia, Inc. and the investors named therein</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm"><span style="color: #0000ee">Promissory Note and Agreement dated May 3, 2020</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922072110/tm2218686d1_ex10-1.htm"><span style="color: #0000ee">Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm"><span style="color: #0000ee">Form of Notice of Stock Option Grant and Award Agreement</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2018</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm"><span style="color: #0000ee">Form of Restricted Stock Award Agreement</span></a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2018</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm"><span style="color: #0000ee">License Agreement by and between Eyenovia, Inc. and Arctic Vision (Hong Kong) Limited, dated August 10, 2020</span></a></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm"><span style="color: #0000ee">License Agreement by and between Eyenovia, Inc. and Bausch Health Ireland Limited, dated October 9, 2020</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 13, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921011530/tm214882d1_ex10-1.htm"><span style="color: #0000ee">First Amendment to Executive Employment Agreement, dated February 1, 2021, by and between the Company and Michael M. Rowe</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921063815/tm2115655d1_ex10-1.htm"><span style="color: #0000ee">Loan and Security Agreement, by and between Eyenovia, Inc. and Silicon Valley Bank, dated May 7, 2021</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 10, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921138092/eyen-20210930xex10d3.htm"><span style="color: #0000ee">First Amendment to Loan and Security Agreement, by and between Eyenovia, Inc. and Silicon Valley Bank, dated September 29, 2021</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 12, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921146432/tm2134583d1_ex10-1.htm"><span style="color: #0000ee">Waiver Agreement, by and between Eyenovia, Inc. and Silicon Valley Bank, dated November 30, 2021</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 3, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465921149554/tm2135048d1_ex1-2.htm"><span style="color: #0000ee">Sales Agreement, by and between Eyenovia, Inc. and SVB Leerink LLC, dated December 14, 2021</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-261638</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 14, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922030903/tm228411d1_ex10-1.htm"><span style="color: #0000ee">Securities Purchase Agreement by and between Eyenovia, Inc. and Armistice Capital Master Fund Ltd., dated March 3, 2022</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 7, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822000649/eyen-20211231xex10d23.htm"><span style="color: #0000ee">Addendum to Executive Employment Agreement, dated March 10, 2022, by and between the Company and Tsontcho Ianchulev</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822000649/eyen-20211231xex10d24.htm"><span style="color: #0000ee">Addendum to Executive Employment Agreement, dated March 10, 2022, by and between the Company and John Gandolfo</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822000649/eyen-20211231xex10d25.htm"><span style="color: #0000ee">Addendum to Executive Employment Agreement, dated March 10, 2022, by and between the Company and Michael Rowe</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465922059563/tm2215251d1_ex10-1.htm"><span style="color: #0000ee">Third Amendment to Loan and Security Agreement, dated as of May 6, 2022, by and between Eyenovia, Inc. and Silicon Valley Bank.</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.26*#</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822002278/eyen-20220630xex10d2.htm"><span style="color: #0000ee">Employment Agreement, dated July 26, 2022, by and between Eyenovia, Inc, and Michael Rowe</span></a></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-Q</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.2</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">August 11, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.27*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822002278/eyen-20220630xex10d3.htm"><span style="color: #0000ee">Executive Chair Agreement, dated August 1, 2022, by and between, Eyenovia, Inc. and Tsontcho Ianchulev</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-Q</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">August 11, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.28</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057822003306/eyen-20220930xex10d1.htm"><span style="color: #0000ee">Non-Employee Director Compensation Policy, as amended</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-Q</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">November 14, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.29</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex10d30.htm"><span style="color: #0000ee">Loan and Security Agreement, dated November 22, 2022, by among Eyenovia, Inc., Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.30</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.30</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex10d31.htm"><span style="color: #0000ee">Supplement to the Loan and Security Agreement, dated November 22, 2022, by among Eyenovia, Inc., Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.31</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.31</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex10d32.htm"><span style="color: #0000ee">Subscription Agreement, dated November 22, 2022, by and among Eyenovia, Inc., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.32</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.32</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex10d33.htm"><span style="color: #0000ee">Employment Agreement, dated December 19, 2022, by and between Eyenovia, Inc. and Bren Kern</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.33</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">1</span><span style="font-size: 10pt; color: black">0.33</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923054420/tm2314185d1_ex10-34.htm"><span style="color: #0000ee">Form of Restricted Stock Unit Agreement</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10</span><span style="font-size: 10pt; color: black">-K/A</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.34</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">May 1,
    2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.34</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923075268/tm2319705d1_ex10-1.htm"><span style="color: #0000ee">Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">June 27, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.35#</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823002416/eyen-20230930xex10d1.htm"><span style="color: #0000ee">License Agreement, dated August 15, 2023, by and between Eyenovia, Inc. and Formosa Pharmaceuticals, Inc.</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10-Q</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">November 13, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.36</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/tm2324923d1_ex10-1.htm"><span style="color: #0000ee">Securities Purchase Agreement, dated August 24, 2023</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">August 29, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.37</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/tm2324923d1_ex10-2.htm"><span style="color: #0000ee">Warrant Amendment Agreement, dated August 24, 2023</span></a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">8-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">10.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">August 29, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38#</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231xex10d38.htm" style="-sec-extract: exhibit">Mutual Termination and Reassignment, dated January 12, 2024, by and between Eyenovia, Inc and Bausch + Lomb Ireland Limited</a></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231xex23d1.htm" style="-sec-extract: exhibit">Consent of Marcum LLP</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231xex31d1.htm" style="-sec-extract: exhibit">Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057824000226/eyen-20231231xex31d2.htm" style="-sec-extract: exhibit">Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm2412633d1_ex31-3.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.4</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm2412633d1_ex31-4.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex32d1.htm">Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1682639/000141057823000511/eyen-20221231xex32d2.htm">Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 18, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline interactive data files pursuant to Rule 405 of Regulation S-T: (i) Balance Sheets as of December 31, 2023 and 2022; (ii) Statements of Operations for the Years Ended December 31, 2023 and 2022; (iii) Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022; (iv) Statements of Cash Flows for the Years Ended December 31, 2023 and 2022; and (v) Notes to Financial Statements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File &#8211; the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management contract or other
compensatory plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">#&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain confidential portions
of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential
portions (i) are not material and (ii) is the type of information that the Company treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements of Sections 13 or
15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this amendment no. 1 to the report to be signed on its
behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EYENOVIA,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 26, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Rowe</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Rowe</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WcpWe/ExsYgsQiJ6XXKMJd2R2c3qk/rLViUaLgzDvWeuEKHY0Fo3yHBZlQWcsO0a5RBKrJHRXNEnsu0uBb9LvGnrWBk3nj8wI8+gZ5YzKZU3xmivLVYpRMlcDoIoTpMYjnsRDH5GptYVGqdVA8pUcGTqWKNT/J4+nNSLDLXvseqMbDWZFBazaLI/IKOFhAP16kl8t1AUmQjCcQKxYXp0PpW/HJqBhLzB1tfZif4r+AIGN0qM -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>2
<FILENAME>tm2412633d1_ex31-3.htm
<DESCRIPTION>EXHIBIT 31.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Michael Rowe, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this amendment no. 1 to the annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2023; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-left: 6.45pt; text-indent: -6.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 26, 2024</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 6.45pt; text-indent: -6.45pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Michael Rowe</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Michael Rowe</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.4
<SEQUENCE>3
<FILENAME>tm2412633d1_ex31-4.htm
<DESCRIPTION>EXHIBIT 31.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL FINANCIAL AND
ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, John Gandolfo, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this amendment no. 1 to the annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2023; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-left: 6.45pt; text-indent: -6.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 26, 2024</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 6.45pt; text-indent: -6.45pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eyen-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaKP6bOdzZR+GYkxtmBwbYkqPyYnjvawCiym88yGgZUF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:EYEN="http://eyenoviabio.com/20231231" elementFormDefault="qualified" targetNamespace="http://eyenoviabio.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://eyenoviabio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>eyen-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>eyen-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyenoviabio.com/role/Cover" xlink:href="eyen-20231231.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://eyenoviabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139880737862928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 16, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EYENOVIA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1178401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">295 Madison Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;2400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">NEW YORK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">393-6684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,957,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4FS6QF\V)%]EJ\7G7$H>9A^7C'I,I ? ]\^<R^U&>H+=_U 8_ =02P,$%
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M[D3FJ,\<];%>+B3K/QB/VR<VCWNE<1R&481E-,N<"C(L;U$$7W<T3!MX8#S
M]'NYQG<;KY"GZP#;TZ<J!%LI7HG82O%< ^+.&WC$L7NW,1[PP'8!JQW@=_-
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M<F]P<R]A<' N>&UL4$L! A0#%     @ $$":6-6VU;+N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $$":
M6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  00)I8*OP<"5L'  "M,   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $$":
M6++WPF_N @  B0X   T              ( !G@\  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  00)I8EXJ[',     3 @  "P              @ &W$@
M7W)E;',O+G)E;'-02P$"% ,4    "  00)I8JL0B%C,!   B @  #P
M        @ &@$P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $$":6"0>
MFZ*M    ^ $  !H              ( ! !4  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ $$":6&60>9(9 0  SP,  !,
M     ( !Y14  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&+Q<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>36</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2412633d1_10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyenoviabio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-60549-DocumentFinStmtErrorCorrectionFlag-Missing] Submission type 10-K/A should have a non-empty value for DocumentFinStmtErrorCorrectionFlag in the Required Context. tm2412633d1_10ka.htm </Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  tm2412633d1_10ka.htm 24</Log>
  </Logs>
  <InputFiles>
    <File>eyen-20231231.xsd</File>
    <File>eyen-20231231_lab.xml</File>
    <File>eyen-20231231_pre.xml</File>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" isUsgaap="true" original="tm2412633d1_10ka.htm">tm2412633d1_10ka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2412633d1_10ka.htm": {
   "nsprefix": "EYEN",
   "nsuri": "http://eyenoviabio.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "eyen-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "eyen-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eyen-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2412633d1_10ka.htm"
     ]
    }
   },
   "keyStandard": 36,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 62,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 36
   },
   "report": {
    "R1": {
     "role": "http://eyenoviabio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2412633d1_10ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2412633d1_10ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://eyenoviabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-052455-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-052455-xbrl.zip
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M+IWWF,FSV*L)/!93R:>[-,(\Q3SL=QJSCX#M#L+@TT/0WP7[AMVC"XK!5[5
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M@IH\),5\\!Y*0+U;6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=>F.\SX5G:
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MIL)QBDUK1IIU<4BI-CQ!Z=8R2\KKFZ[E)[E9;Y)_K7!*Y);_ E!+ P04
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MI(<21XGUZHWBDA]JG5'U6OX5J:"M@!+V04TWW<_0.+/=WJK;&S^Z'3.>7N9
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ME6K;O1UV_I%=?3YF,4$5"JEFZPI_+NU7JH)N(J# /Z[0BHB(#O(FW+\"#^R
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MXNG1CFCNHIT:^ Y5)A'=43YSPX*WMD\O/N^HYVE*R<SCTU+F45A,%B?"LAO
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M[?7'LLA)U#26N?SO !8TI'M=6'0D0+VO5B_6MHV=[?(.J7/TL8L?E:DDTC,
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MG*MSFF-_(O)$[@K2'@6.=)5\GJ>MF4*3 OLN0@<VW;K%VCAX3PQ."4N2,0-
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M0A 5.SVQ;>=F66<43:8]"KW$"2V6[I9!V\CM^HYE.;>D8!/S!.Y'#!*T7J7
MFC9\'@IX=1TX;==6"GDWCNT2NO"]+=@K/!3*$;;-[[I6@-86.W4+#)NRPSDY
M# 6+P6R0*3W4T65#6T=<,M@)I57?],">8F-NN(RDCW8$!X;'RBK27_ENB2>R
M>)/R/9.*,QA1EC'R0#%4?]UG;:HDXK0AF=+$.VE-G.X&[^*&8#+;N76-'/L8
MD\:%2K/0MZ:G1&>LXCV34(VTW[B6&Q\$8(1#_[I5WGK"MK-LAYQ!\9'#&X#-
M-N]]Z+AO#S1 ])%AH@HE/G<-;R#^VOYE9[% >UV0;_M.]Z> +*F27@1E<0]$
M7@/9P#P_F)^3ZKT!^E*!WE0*D&0H<5-ZPUCRA_>5XQO68B&;[WU1NA4E=8YJ
M]4V>X+CRX)LNZ'<G8!\, HO?Z.RT<%3 ?R\*G^<M/#Q;Q8D4IC>/*N<6>SM'
M1'C -N('L/=FV9?[BF3(/"O8-X?VP$.KWGM=-I.OW /,2K[ 3-2%FZL(WZOE
M *F%+!B?YL&?>U987@"JU-<,59[P=G'1!UQ_Z@'G3 N)"BSK<L"O4+"4JSEK
M W.IJG-6#:?\B<7MO>WS$7HM#[G]%PQISUM:_SX'W,-K&KQ=P4H&8A?BWU)%
MWZNM;F/%50>?^O?1)6,V4%P;*#Y&!"U4,]A=65"M.L+EPO5R=]TL<O>G9G=@
M<(M]XI;_#S<M[CY?EXA5QX[XOWMZH[RZE?56$9+8YVPUZG\UEF&D+.;8EM/-
MHS:M;>6R3VI_54]J(_.?!2D>:F,_FZBHY2$?ULBPOC2Z ] B?C.Z3L=SEE14
M>A6E7!P)ZK7'5KQ\M4K"8[W6:QK56&,E875.:BE!A8V2\.IX4:F:!_]>*V]
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MHP#0X>S,@9642E1B,G!9W\1J129V7_)AC:+P(Q8&PW)3HM#/)<&'RL [[A
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M4I?G?3ZC@\7<'2KRF'^9Z\VUH\9WCL3/>[N/:*;Q_*!XPOP9-U0V6+RN6&S
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MH466LWE!A+#J5F10,"]2?]VPH-RS'B^HS<LXH.PA&0=LU"!-?L(BN@<J>7+
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MZ27T_:D=HKY_Y7MA[$9(_GXA;P]<B#R]]Z^YD\VY+5LK8T]G@7.-+*ZG;$2
M\.9K[$0S_D!EE?^2V-+W&]#JZ-%W5?Y&P0'6[SDD%0*J1Q.55?]6[=2_H.KN
M@_KO==I[T77;,#N]KE#_G5+Y!C:,\=I5[<UDZOHS,OD7%']"*6G0T77<8'-N
M0>:^:_K^8P@O.AS[VK'M#<>QRZXKJ_._H3#AJ=K[QMJ'(!Z)ZE2H_+Y2^95L
MHK(JO[5E*K],A.>A5/Y;?^QIO\ GW[WTE;;? FU?L>B.TO;U:**RVKZ]9=J^
MK[2]TO8;T_;]:@U):?MZ-%%9;5_:5ZV%LC?7.>CXWO=&3CAT_3 .6%,["$.8
M9M+\=*?:-7QR?"\D10[/#D&OL\BA2P<2:% ZO?XZO8CA2^ETI=-KJ].[];7@
M6[K>[Z)2-[LMHR<L^#(%FG.Y54R\BF0J?H&J'(S[,Q=?Q :5SJ\OJZSVOMA9
M^[SG(V18+<OL5FQ<:))7N:92*>^*-E%9Y=W;,N7=7L\B_QK#Y%XZ;*1=1/[P
MB_9A6A.#6ZGL-51VQ9P I;+KT$1E57;IF&!E-/:JJT<PC&*54-KG[,H)(W[I
MO';N7(VC@F)(<9>#Q4N-5Y9"8NS<\6#4D1^$F@<F.GT7,.<^=]JK*$L5AH51
MEK4O[WD,+L.B6T:4RJ],$Y55^>7+>BNG\]N];E_H_%[?Z*]U#/8L\"=.&/K!
M#&SUB)'>3@]!294_TZR*'U]2>KNV1U91O.:/1"NE7:4FJJNTC?K%5B0%>=>$
MST1!#H9ZKR.U=BFVG+RM?<!CWZ2[S\':)J6-8*!]F'C.( Y%Y"4?-E>JO/ZJ
MO&)YSK>QQS1CG@)?Z?(J-5%=75Z_8Z@B3M[3K99IFGO1=:O?[EOM-9*<:9P<
M5H#AIUR0_!=B0B6;_,8.1C4(FBOE7=LT)]?>/&+>4]J[DDU45WO7]A3I$NV]
M3I83C>[ &49)CE-IZ^W3UA4;TMW:NH!8.F'N7485G7F@!/FSI<B?B?S9J#WY
M\S+!4&S.=YAPA6QILOG:\CG?2:G6*T.I]@TTFC P6&+M#R=$]^?YK[YWI;V#
M_[S03IR) P#[;;1J)82C0A3$Q41L=7J'E3!>IQ?!=$EAM=7#OL1F54'UZ>'6
M;%8]?L_'J^M&MFM+/PK^I-$R"2LML]_JKI/0^1:H/+3C<#C6?F6V&XVUXX"Y
M^.T<3'X81CYR@_7O"9-K"]N#^ZB5'.LWXMYW'/%=%QY4:K!2FHWY:A2%9$_U
M\>HB6:=^ 5&.9 9\:EM4FF"T>CUS'2 [<@*P-'-W*ZS+Q$%;V[B3B./4&8YM
MYFJGNS U-TPAFT*V&B-;(OX<V0R%;$_^\>HB6[>N/IJA=ZR>T29D,]J==GLM
M'\V'O_%['X9Q@,?0,R!6XK8(QW6&OH<)$Y?-P'OSOC0S]=7=N7VO8$S!6/U@
M#"59A.05A*G'JPMAO=I"F&'U]+ZYQP!A=G";Z7U+OT40&Y4YXEG@GST<KEVP
M:<2O)A"W8-<2WM;/QRE\6_,"@MH,-KD)QC 5R*G'*PYR=64Q,(Q6IV51*LVP
M6NV>M8Z;]LF&'H*-85BRXZUYL[9&$*8\-.6AS=\6I0*-ZO&* YA95TH& +!^
MN]WB -;66Z)N<L<L@5\7MIN_@[ $?/UQJ)TP>!_OBW9R\DI"5WHQ7*N^T'6Q
M4Q_O@/C9.D;'6K-B\'MBUV[A!8N5'.MR>5;8]50?KRYVE3Z:7S'L,G5+[^M4
M\V_V6H:QCN\E(H@.#/HLAN[LM:O_)TY(!Z%?V5,GLEU-7--[%&-I8^96=<[U
M9<TQ#=0(UY1+IERR'&]==5DS*J'HG]#CU<6TTI=Q5P736H;>[O8 TW2]T^JG
M23/#M R>-"M%C'HP&C%O%$_*ES/R/2U2X>;FKPVNI"(#*T&!VL/NP/HXP\)"
MTQ6LJ<<K#FNE>8QK!&MER*<>'-;6N2RSDDI,(=J#;[Y"$JQ*CE8AFGJ\)HA6
MFEFN1HA6AI#KP1%-GCJKZY$S!6@/OO?J,UH%:.KQF@!::?*]J@!:DDUK]]L=
MGDTSVF9[K73:Q[&#+)*EB_4YHMDA4E+B29S.$E K5P&Y6T=\4VDUE5;+GD5K
M*VQ3C^>7?34MZOT(45N*$)4(44U%B+K>\FP!(>J^)NR7 4HU-]LZ/VXG/VH:
MKC#-;B\)5YAZ1Q[&+%/JNRHN\39V9YI9RH)K;BXR434"SD69JCLWZOP;;0E3
M:M'FKS=MZOP;21)50UF4ZO'*1DN*]F&W=D1T=\-KF:JM- 'P:FP[P2+&RBU=
M#++-HCC)-A1JW1]4*S/TNH50"K9G72JZ%!ZJQ[<##PM/Y]4##BU+[V3@,*'^
M*9-->.][.]SC9$Q[[01L&/D!);>9%]ITW>"9[SK#61-3"#:_4U:AFT*W^VRV
MNJ0+YH>>$OVT%+ZIQVN%;[6C_1'X9L'GMF&D^)86?UGZ?0E:Y]A\3#/K]$WP
MFJF\M]?4#JZ9%V=/HGKV%3_(>GS<U$YVS])G_H!OXX!I'Z93/XABCQ^!Q4.K
M_$%^N/6N9Y-VMP)TZY*'WT+0M0IY4VHP=E&0QEU*2T'NDW^\)I!;O.%J#KFE
M"!_BZ=1ELC@-BZ45"%=&FRH0_JXZH:ZNKP)A]7@M0;AVC$LE0+@48V \"(>!
M,Z40;EFT!:1;B;@*316:5F7\N+GK0E.HT%0]OA5H6E>NIU5H6JIJ:$51;LI
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MYH]7<@X>JTRL%/U(/[2UL[$=3.PABVF90_Y$_?%0G451@'B?LRB6 D7U>*U
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MB:J"TO<(V+_RK[&D!0^&'F> Z34"$PJS1AK<V"=%.Z2'\:BJ]N?A^8D6V5>
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M8DBTB 2X)$&D3&D.%G(' AQ9E>=$[K1(2FYH0;M[FSFNA0@&729ZM](^M$#
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MTJA+9*?(M*6/Z^7Y71_S_P)02P,$%     @ $$":6%OZ&US  P  ]P\  !8
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M,C R,S$R,S$N>'-D4$L! A0#%     @ $$":6&MQC:Q9"P  -HP  !4
M         ( !70,  &5Y96XM,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M !! FEA-.L.LB <  -1;   5              "  >D.  !E>65N+3(P,C,Q
M,C,Q7W!R92YX;6Q02P$"% ,4    "  00)I8]6MW*\B8  #UP@4 %
M        @ &D%@  =&TR-#$R-C,S9#%?,3!K82YH=&U02P$"% ,4    "  0
M0)I8<WR!0[@#  #M#P  %@              @ &>KP  =&TR-#$R-C,S9#%?
M97@S,2TS+FAT;5!+ 0(4 Q0    ( !! FEA;^AM<P ,  /</   6
M      "  8JS  !T;3(T,3(V,S-D,5]E>#,Q+30N:'1M4$L%!@     &  8
*CP$  'ZW      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2412633d1_10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eyen-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000005">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000006">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000007">0001682639</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000013">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000017">001-38365</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000018">EYENOVIA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000020">47-1178401</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000021">295 Madison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000022">Suite&#160;2400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000023">NEW YORK</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000024">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000025">10017&#160;</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">(833)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000027">393-6684</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000028">Common Stock, $0.0001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000029">EYEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000031">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000038">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000039">688</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000040">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000041">New York, NY</dei:AuditorLocation>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="-5"
      id="Fact000042"
      unitRef="USD">88000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-04-16"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">50957869</dei:EntityCommonStockSharesOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
